Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

33.07
-0.5400-1.61%
Post-market: 32.42-0.6492-1.96%19:30 EDT
Volume:1.57M
Turnover:51.80M
Market Cap:1.97B
PE:-4.72
High:33.40
Open:33.29
Low:32.77
Close:33.61
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:1.66
T/O Rate:3.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.92
PE(LYR):-4.64

Loading ...

Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Apr 02

Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and Agios Pharma (AGIO)

TIPRANKS
·
Apr 01

Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?

Benzinga_recent_news
·
Apr 01

Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating

TIPRANKS
·
Mar 31

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Benzinga
·
Mar 31

Agios Pharmaceuticals Plans Accelerated Approval Filing for Mitapivat in Sickle Cell Disease

MT Newswires Live
·
Mar 31

Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat

TIPRANKS
·
Mar 31

Agios Pharmaceuticals Inc: Plans to Submit Mitapivat Snda in Sickle Cell Disease in Coming Months

THOMSON REUTERS
·
Mar 31

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-Snda Meeting With FDA

THOMSON REUTERS
·
Mar 31

Agios Pharmaceuticals Principal Accounting Officer Theodore James Jr. Washburn Reports Disposal of Common Shares

Reuters
·
Mar 06

Agios Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 06

Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug

Simply Wall St.
·
Mar 04

Agios Pharmaceuticals Inc - Newbridge to Manage Pyrukynd Commercialization in Gulf

THOMSON REUTERS
·
Mar 02

Agios’ Pyrukynd® (Mitapivat) Approved for Adults With Thalassemia in the United Arab Emirates

THOMSON REUTERS
·
Mar 02

UAE Regulator Approves Agios PYRUKYND for Adult Thalassemia

Reuters
·
Mar 02